Overview

This trial is active, not recruiting.

Condition colorectal cancer
Treatments fluorouracil, leucovorin calcium, surgical procedure
Phase phase 3
Sponsor Eastern Cooperative Oncology Group
Collaborator National Cancer Institute (NCI)
Start date August 1993
Trial identifier NCT00002525, ACOSOG-E1292, CDR0000078337, CLB-9395, E-1292, INT-0136, NSABP-C1-63, SWOG-9250

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known if surgery is more effective with or without chemotherapy for colon cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of fluorouracil plus leucovorin with that of no further therapy in treating patients who have stage II or stage III colon cancer that can be surgically removed.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Primary purpose treatment

Eligibility Criteria

Male or female participants at least 18 years old.

DISEASE CHARACTERISTICS: Adenocarcinoma of the colon documented by colonoscopy or barium enema Tumor either considered resectable or totally resected within 24 hours prior to study No dual primary tumors Randomization within 2 weeks prior to surgery or within 24 hours after surgery required Patients randomized after surgery must meet the following criteria: Complete resection performed with no evidence of residual disease or distant metastases Distal margin of tumor above the peritoneal reflection in area of rectum No free perforation Intestinal obstruction allowed Preliminary or complementary colostomy allowed Concurrent registration for E-3293 strongly recommended PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2.0 mg/dL Renal: Creatinine no greater than 2.0 mg/dL Other: No prior nonmalignant systemic disease that would preclude use of chemotherapy No second malignancy within 5 years except: Superficial nonmelanomatous skin cancer Carcinoma in situ of the cervix Not pregnant or nursing Fertile patients must use adequate contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior fluorouracil No other prior or concurrent chemotherapy for this malignancy Endocrine therapy: Not specified Radiotherapy: No prior or concurrent radiotherapy for this malignancy Surgery: See Disease Characteristics

Additional Information

Official title PHASE III INTERGROUP PROSPECTIVELY RANDOMIZED TRIAL OF PERI-OPERATIVE 5-FU AFTER CURATIVE RESECTION, FOLLOWED BY 5-FU/LEVAMISOLE FOR PATIENTS WITH COLON CANCER
Description OBJECTIVES: I. Compare survival, disease free survival, and locoregional and distant metastases recurrence rates of patients with stage IIC or stage III colon cancer treated with curative colon resection with or without perioperative fluorouracil, followed by fluorouracil and leucovorin calcium. II. Compare survival and disease free survival in patients with stage IIB colon cancer treated with curative colon resection with or without perioperative fluorouracil. OUTLINE: This is a randomized study. Patients undergo curative colon resection via laparotomy. Patients are randomized to 1 of 2 arms. Arm I: Within 24 hours of the colon resection, patients receive perioperative fluorouracil IV over 24 hours for 7 days. Arm II: Patients receive no perioperative fluorouracil. After surgery, patients with stage I, stage IIA, or stage IV colon cancer are immediately removed from study. Patients with stage IIB, IIC, or III colon cancer are reregistered within 35 days postoperatively. Beginning 21-35 days after surgery, patients with stage IIC or III disease receive leucovorin calcium IV bolus immediately followed by fluorouracil IV bolus on days 1-5. Courses repeat every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stage IIB disease do not receive adjuvant fluorouracil and leucovorin calcium. Patients are followed every 3 months for 2 years, then every 6 months for 2 years, and then annually. PROJECTED ACCRUAL: A total of 800-2,000 patients (at least 400 per treatment arm) will be accrued for this study over 2-3 years.
Trial information was received from ClinicalTrials.gov and was last updated in April 2013.
Information provided to ClinicalTrials.gov by Eastern Cooperative Oncology Group.